Compare QRVO & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QRVO | COGT |
|---|---|---|
| Founded | 1957 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 6.6B |
| IPO Year | 2014 | 2018 |
| Metric | QRVO | COGT |
|---|---|---|
| Price | $87.32 | $38.39 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 15 |
| Target Price | ★ $90.64 | $36.21 |
| AVG Volume (30 Days) | 1.3M | ★ 2.7M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 524.14 | N/A |
| EPS | ★ 3.62 | N/A |
| Revenue | ★ $3,678,517,000.00 | $7,871,000.00 |
| Revenue This Year | $0.81 | N/A |
| Revenue Next Year | N/A | $1,733.58 |
| P/E Ratio | $24.17 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $75.43 | $8.80 |
| 52 Week High | $109.49 | $43.73 |
| Indicator | QRVO | COGT |
|---|---|---|
| Relative Strength Index (RSI) | 36.52 | 70.58 |
| Support Level | $77.24 | $37.54 |
| Resistance Level | $92.40 | $40.62 |
| Average True Range (ATR) | 4.13 | 1.51 |
| MACD | -1.37 | 0.53 |
| Stochastic Oscillator | 3.40 | 81.96 |
Qorvo represents the combined entity of RF Micro Devices and TriQuint Semiconductor, which merged in January 2015. The company specializes in radio frequency filters, power amplifiers, and front-end modules used in many of the world's most advanced smartphones. Qorvo also has a suite of products sold into a variety of non-smartphone end markets, such as wireless base stations, cable TV and networking equipment, and infrastructure and military applications.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.